Genetics to epigenetics: targeting histone deacetylases in hormone receptor-positive metastatic breast cancer

被引：9
作者：
Wander, Seth A. [1 ]
Spring, Laura M. [1 ]
Bardia, Aditya [1 ]
机构：
[1] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02115 USA
来源：
LANCET ONCOLOGY | 2019年 / 20卷 / 06期
关键词：
D O I：
10.1016/S1470-2045(19)30279-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：746 / 748
页数：4
相关论文
共 10 条
  • [1] Andre F., 2018, Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): results of the Phase 3 SOLAR-1 trial, European Society for Medical Oncology, Munich, Germany, 2018
  • [2] Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
    Baselga, Jose
    Campone, Mario
    Piccart, Martine
    Burris, Howard A., III
    Rugo, Hope S.
    Sahmoud, Tarek
    Noguchi, Shinzaburo
    Gnant, Michael
    Pritchard, Kathleen I.
    Lebrun, Fabienne
    Beck, J. Thaddeus
    Ito, Yoshinori
    Yardley, Denise
    Deleu, Ines
    Perez, Alejandra
    Bachelot, Thomas
    Vittori, Luc
    Xu, Zhiying
    Mukhopadhyay, Pabak
    Lebwohl, David
    Hortobagyi, Gabriel N.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (06) : 520 - 529
  • [3] Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial
    Jiang, Zefei
    Li, Wei
    Hu, Xichun
    Zhang, Qingyuan
    Sun, Tao
    Cui, Shude
    Wang, Shusen
    Ouyang, Quchang
    Yin, Yongmei
    Geng, Cuizhi
    Tong, Zhongsheng
    Cheng, Ying
    Pan, Yueyin
    Sun, Yuping
    Wang, Hong
    Ouyang, Tao
    Gu, Kangsheng
    Feng, Jifeng
    Wang, Xiaojia
    Wang, Shubin
    Liu, Tianshu
    Gao, Jinghua
    Cristofanilli, Massimo
    Ning, Zhiqiang
    Lu, Xianping
    [J]. LANCET ONCOLOGY, 2019, 20 (06) : 806 - 815
  • [4] HDACs and HDAC Inhibitors in Cancer Development and Therapy
    Li, Yixuan
    Seto, Edward
    [J]. COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2016, 6 (10):
  • [5] Functional Activation of the Estrogen Receptor-α and Aromatase by the HDAC Inhibitor Entinostat Sensitizes ER-Negative Tumors to Letrozole
    Sabnis, Gauri J.
    Goloubeva, Olga
    Chumsri, Saranya
    Nguyen, Nguyen
    Sukumar, Saraswati
    Brodie, Angela M. H.
    [J]. CANCER RESEARCH, 2011, 71 (05) : 1893 - 1903
  • [6] CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions
    Spring, Laura M.
    Wander, Seth A.
    Zangardi, Mark
    Bardia, Aditya
    [J]. CURRENT ONCOLOGY REPORTS, 2019, 21 (03)
  • [7] Street Insider, SYND PHARM SNDX SAYS
  • [8] CANCER THERAPY PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D
    Toska, Eneda
    Osmanbeyoglu, Hatice U.
    Castel, Pau
    Chan, Carmen
    Hendrickson, Ronald C.
    Elkabets, Moshe
    Dickler, Maura N.
    Scaltriti, Maurizio
    Leslie, Christina S.
    Armstrong, Scott A.
    Baselga, Jose
    [J]. SCIENCE, 2017, 355 (6331) : 1324 - 1329
  • [9] Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor
    Yardley, Denise A.
    Ismail-Khan, Roohi R.
    Melichar, Bohuslav
    Lichinitser, Mikhail
    Munster, Pamela N.
    Klein, Pamela M.
    Cruickshank, Scott
    Miller, Kathy D.
    Lee, Min J.
    Trepel, Jane B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (17) : 2128 - +
  • [10] E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer
    Yeruva, Sri Lakshmi Hyndavi
    Zhao, Fengmin
    Miller, Kathy D.
    Tevaarwerk, Amye J.
    Wagner, Lynne I.
    Gray, Robert J.
    Sparano, Joseph A.
    Connolly, Roisin M.
    [J]. NPJ BREAST CANCER, 2018, 4
1